CIK 0001799448
- Non-accelerated filer
- Smaller reporting company
Aligos Therapeutics, Inc.
Sign in to watch- Ticker
- ALGS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 800-466-6059
- Business address
- ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-09 | BLATT LAWRENCE President and CEO | Grant or award · Stock Option (Right to Buy) | +105,840 | 105,840 | ||
| 2025-07-16 | BLATT LAWRENCE President and CEO | Grant or award · Stock Option (Right to Buy) | +179,800 | 179,800 | ||
| 2025-02-28 | BLATT LAWRENCE President and CEO | Grant or award · Stock Option (Right to Buy) | +140,103 | 140,103 | ||
| 2024-09-04 | BLATT LAWRENCE Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +33,920 | 33,920 | ||
| 2024-03-01 | BLATT LAWRENCE Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +965,435 | 965,435 | ||
| 2024-02-28 | BLATT LAWRENCE Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +132,352 | 132,352 | ||
| 2024-02-28 | BLATT LAWRENCE Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +230,999 | 230,999 | ||
| 2024-02-28 | BLATT LAWRENCE Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +57,749 | 57,749 | ||
| 2024-02-27 | BLATT LAWRENCE Chief Executive Officer | Returned to the company · Stock Option (Right to Buy) | −450,000 | 0 | ||
| 2024-02-27 | BLATT LAWRENCE Chief Executive Officer | Returned to the company · Stock Option (Right to Buy) | −323,400 | 0 | ||
| 2024-02-27 | BLATT LAWRENCE Chief Executive Officer | Returned to the company · Stock Option (Right to Buy) | −80,850 | 0 | ||
| 2023-10-25 | BLATT LAWRENCE Chief Executive Officer | Grant or award | +610,277 | $0.76 | $462K | 1,847,575 |
| 2023-10-25 | BLATT LAWRENCE Chief Executive Officer | Grant or award · Warrants (Right to Buy) | +305,138 | $0.13 | $38K | 305,138 |
| 2023-09-08 | BLATT LAWRENCE Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2023-03-15 | BLATT LAWRENCE Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +242,500 | 242,500 | ||
| 2022-07-07 | BLATT LAWRENCE Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +161,700 | 161,700 | ||
| 2022-02-04 | BLATT LAWRENCE Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +323,400 | 323,400 | ||
| 2022-02-04 | BLATT LAWRENCE Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +80,850 | 80,850 | ||
| 2020-12-01 | BLATT LAWRENCE Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +450,000 | 450,000 | ||
| 2020-10-20 | BLATT LAWRENCE Chief Executive Officer | Conversion | +41,016 | 41,016 |
Page 1 of 2 · 39 trades